Chemotherapeutic Evaluation of a Synthetic Tubulysin Analogue-Dendrimer Conjugate in C26 Tumor Bearing Mice

William C. Floyd, Gopal K. Datta, Shinichi Imamura, Heidi M. Kieler-Ferguson, Katherine Jerger, Andrew W. Patterson, Megan E. Fox, Francis C. Szoka*, Jean M.J. Fréchet, Jonathan A. Ellman

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    31 Scopus citations

    Abstract

    Conjugate to ameliorate! Polymeric drug delivery using a synthetic tubulysin analogue in C26 tumor bearing mice is described. A single dose of this conjugate (shown) resulted in a 90 % increase in the average lifespan of the mice as compared to groups given a phosphate-buffered saline control or the free tubulysin analogue. Moreover, 37 % of the mice given the polymeric formulation were tumor free at the conclusion of the study.

    Original languageEnglish (US)
    Pages (from-to)49-53
    Number of pages5
    JournalChemMedChem
    Volume6
    Issue number1
    DOIs
    StatePublished - Jan 3 2011

    Keywords

    • Antitumor agents
    • Colon carcinoma
    • Dendrimers
    • Drug delivery
    • Tubulysins

    ASJC Scopus subject areas

    • Drug Discovery
    • Molecular Medicine
    • Biochemistry
    • Pharmacology, Toxicology and Pharmaceutics(all)
    • Pharmacology
    • Organic Chemistry

    Fingerprint

    Dive into the research topics of 'Chemotherapeutic Evaluation of a Synthetic Tubulysin Analogue-Dendrimer Conjugate in C26 Tumor Bearing Mice'. Together they form a unique fingerprint.

    Cite this